CHAPTER 7: TREATMENT OF OBESITY. ARGLP-1, NALTREXONE-BUPROPION, BARIATRIC SURGERY
DOI:
https://doi.org/10.47196/diab.v58i2Sup.790Keywords:
obesity, diabetes mellitus, chronic kidney diseaseAbstract
Obesity increases the risk of CKD through different mechanisms, including excessive production of proinflammatory cytokines and insulin resistance, lipotoxicity, HBP, and increased GFR pressure. The clinical expression of renal function is initially expressed with an increase in GFR, albuminuria, nodular glomerulosclerosis and tubulointerstitial damage.
The diagnosis of obesity constitutes a challenge in the general population and especially in patients with CKD, since in them visceral fat (evaluable by waist circumference) could have a better correlation than BMI, since the latter does not differentiate the composition body, and in patients with CKD the prevalence of sarcopenia could underestimate the BMI.
References
I. de Vries AP, Ruggenenti P, Ruan XZ. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol 2014 May;2(5):417-26. doi: 10.1016/S2213-8587(14)70065-8..
II. Chintam K, Chang AR. Strategies to treat obesity in patients with CKD. Am J Kidney Dis 2021 Mar;77(3):427-439. doi: 10.1053/j.ajkd.2020.08.016.
III. Madero M, Katz R, Murphy R. Comparison between different measures of body fat with kidney function decline and incident CKD. Clin J Am Soc Nephrol 2017 Jun 7;12(6):893-903. doi: 10.2215/CJN.07010716.
IV. MacLaughlin HL, Cook SA, Kariyawasam D. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis 2010 Jan;55(1):69-76. doi: 10.1053/j.ajkd.2009.09.011.
V. Sandino J, Cordero Garcia-Galán L. Anything new in the treatment of obesity in obese patients with CKD? Nephron 2022;146(6):616-623. doi: 10.1159/000524201.
VI. Jensen EP, Poulsen SS, Kissow H. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am J Physiol Renal Physiol 2015 Apr 15;308(8):F867-77. doi: 10.1152/ajprenal.00527.2014.
VII. Mann JFE, Ørsted DD, Brown-Frandsen K. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.
VIII. Gerstein HC, Colhoun HM, Dagenais GR. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3.
IX. Marso SP, Bain SC, Consoli A. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141.
X. Kristensen SL, Rørth R, Jhund PS. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14. Erratum in: Lancet Diabetes Endocrinol. 2020 Mar;8(3):e2. PMID: 31422062.
XI. Rodbard HW, Dougherty T, Taddei-Allen P. Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. Am J Manag Care 2020 Dec;26(16 Suppl):S335-S343. doi: 10.37765/ajmc.2020.88554.
XII. Aviles-Bueno B, Soler MJ, Pérez-Belmonte L. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice. Clin Kidney J. 2022 Apr 11;15(8):1593-1600. doi: 10.1093/ckj/sfac096.
XIII. Tham JC, le Roux CW, Docherty NG. Cardiovascular, renal and overall health outcomes after bariatric surgery. Curr Cardiol Rep 2015 May;17(5):34. doi: 10.1007/s11886-015-0588-6.
XIV. Consenso Intersocietario de Cirugía Bariátrica y Metabólica, 2019. Argentina. Rev Arg Cirug 2019;113(1):1-70.
XV. Lieske JC, Collazo-Clavell ML, Sarr MG. Gastric bypass surgery and measured and estimated GFR in women. Am J Kidney Dis. 2014 Oct;64(4):663-5. doi: 10.1053/j.ajkd.2014.06.016.
XVI. Sjöström L, Peltonen M, Jacobson P. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014 Jun 11;311(22):2297-304. doi: 10.1001/jama.2014.5988.
XVII. Young L, Nor Hanipah Z, Brethauer SA. Long-term impact of bariatric surgery in diabetic nephropathy. Surg Endosc 2019 May;33(5):1654-1660. doi: 10.1007/s00464-018-6458-8.
XVIII. Imam TH, Fischer H, Jing B. Estimated GFR before and after bariatric surgery in CKD. Am J Kidney Dis 2017 Mar;69(3):380-388. doi: 10.1053/j.ajkd.2016.09.020.
XIX. Sjöström L, Peltonen M, Jacobson P. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014 Jun 11;311(22):2297-304. doi: 10.1001/jama.2014.5988.
XX. Carlsson LM, Romeo S, Jacobson P. The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): a prospective controlled intervention trial. Int J Obes (Lond). 2015 Jan;39(1):169-75. doi: 10.1038/ijo.2014.72.
XXI. Hallersund P, Sjöström L, Olbers T. Gastric bypass surgery is followed by lowered blood pressure and increased diuresis long term results from the Swedish Obese Subjects (SOS) study. PLoS One 2012;7(11):e49696. doi: 10.1371/journal.pone.0049696. Epub 2012 Nov 29. Erratum in: PLoS One 2013;8(5). doi: 10.1371/annotation/88dbb5b7-3f7e-4b26-a5b6-f020d33f0182.
XXII. Peterli R, Steinert RE, Woelnerhanssen B. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 2012 May;22(5):740-8. doi: 10.1007/s11695-012-0622-3.
XXIII. Pournaras DJ, Osborne A, Hawkins SC. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 2010 Dec;252(6):966-71. doi: 10.1097/SLA.0b013e3181efc49a.
XXIV. Docherty NG, le Roux CW. Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease. Exp Physiol 2014 Sep;99(9):1146-53. doi: 10.1113/expphysiol.2014.078790.
XXV. Carlsson LM, Romeo S, Jacobson P. The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): a prospective controlled intervention trial. Int J Obes (Lond) 2015 Jan;39(1):169-75. doi: 10.1038/ijo.2014.72.
XXVI. Ritz E. Bariatric surgery and the kidney-much benefit, but also potential harm. Clin Kidney J 2013 Aug;6(4):368-72. doi: 10.1093/ckj/sfs161.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 on behalf of the authors. Reproduction rights: Argentine Society of Diabetes
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
